Jurnal Internasional Aksi serotonin yang beragam dari vilazodone mengurangi l-3,4-dihidroxyphenylalanine-diinduksi tardive pada tikus hemi-parkinsonian – Meadows – 2018 – Gerakan Gangguan
Background: Serotonergic system is a well-established modulator ldopa-induced dyskinesia. To date, targeting serotonin transporters or serotonin 1A receptor subtypes (5 – HT 1A ) reduced – dopa-induced dyskinesia in animal models; However, this strategy failed to translate clinically. Ideally, compounds that work on both antidemicetic sites that are known to optimize the serotonin-mediated approach. Vilazodone is a selective and partial serotonin reuptake inhibitor 5 – HT. 1A Agonists were approved by the Food and Drug Administration, placing Vilazodone in a unique position to reduce ldopa-induced dyskinesia [uncompromising]. l improvement of the motorbike mediated by DHA.
Purpose: The aim of this study was to characterize the effects of Vilazodone on 1945–006] European-induced behavior, neurochemistry and gene expression in unilateral 6-hydroxydopamine-lesioned hemi-parkinsonian mice. 
Method : In experiments 1 and 2, I-dopa-naïve and l – dopa-primed animals used together with Vilazodone and l – dopa every day for 3 weeks to model subchronic use, and changes in behavioral, neurochemical, and messenger RNA (mRNA) expression were measured. In experiment 3, diskinetic behavior was assessed following 5 – HT  or block 1 serotonin receptor subtypes before Vilazodone – ldopaadministration.
Results : Vilazodone significantly suppressed development and established induced deaf puncture l without sacrificing the promoter effect of therapy [dopa]. In striatum dopamine-exhausted, Vilazodone- l dopa cotreatment increases dopamine content, demonstrates normalization of dopamine kinetics in the diskinetic brain, and reduces leprosy-induced c-Fos and preprodynorphin mRNA overexpression , indicating Dopamine D 1 experienced overactivity of the direct receptor pathway. Only 5 – HT 1977 1A partial antagonism reduced the antidiskinetic efficacy of Vilazodone, showing both the dependent effects of serotonin transporters and 5 – HT 1A receptor in the action of Vilazodone.
Conclusion : Our findings show Vilazodone has a serotonin-dependent effect on rodents  ñdopa-induced dyskinesia and implies the potential to position Vilazodone against l -Dopa‐‐ development of dyskinesia induced and expressed in patients with Parkinson's disease. © 2018 International Parkinson and Movement Disorder Society